The Tyrosine Kinase Inhibitor Dasatinib Reduces the Growth of Intracellular Mycobacterium Tuberculosis Despite Impairing T-Cell Function

European Journal of Immunology - United Kingdom
doi 10.1002/eji.201847656
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2009English

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells

PLoS ONE
Multidisciplinary
2011English

Modelling Ponatinib Resistance in Tyrosine Kinase Inhibitor-Naïve and Dasatinib Resistant BCR-ABL1+ Cell Lines

Oncotarget
Oncology
2018English

The T-Cell Response to Lipid Antigens of Mycobacterium Tuberculosis

Frontiers in Immunology
AllergyImmunology
2014English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

Overexpression of Syk Tyrosine Kinase in Peripheral T-Cell Lymphomas

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

Identification of an Intracellular Metabolic Signature Impairing Beta Cell Function in the Rat Beta Cell Line INS-1E and Human Islets

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Networked T Cell Death Following Macrophage Infection by Mycobacterium Tuberculosis

2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy